CoChat

Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes

Open access
Crawford, Tineke J, Crowther, Caroline A, Alsweiler, Jane, Brown, Julie · 2015 · Cochrane Database of Systematic Reviews
Cited by 96

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Gestational diabetes, glucose intolerance with onset or first recognition during pregnancy, is a rising problem worldwide. Both non-pharmacological and pharmacological approaches to the prevention of gestational diabetes have been, and continue to be explored. Myo-inositol, an isomer of inositol, is a naturally occurring sugar commonly found in cereals, corn, legumes and meat. It is one of the intracellular mediators of the insulin signal and correlated with insulin sensitivity in type 2 diabetes. The potential beneficial effect on improving insulin sensitivity suggests that myo-inositol may be useful for women in preventing gestational diabetes. OBJECTIVES: To assess if antenatal dietary supplementation with myo-inositol is safe and effective, for the mother and fetus, in preventing gestational diabetes. SEARCH METHODS: We searched the Pregnancy and Childbirth Group's Trials Register, ClinicalTrials.gov, WHO ICTRP (2 November 2015) and reference lists of retrieved studies. SELECTION CRITERIA: We sought published and unpublished randomised controlled trials, including conference abstracts, assessing the effects of myo-inositol for the prevention of gestational diabetes mellitus (GDM). Quasi-randomised and cross-over trials were not eligible for inclusion, but cluster designs were eligible. Participants in the trials were pregnant women. Women with pre-existing type 1 or type 2 diabetes were excluded. Trials that compared the administration of any dose of myo-inositol, alone or in a combination preparation were eligible for inclusion. Trials that used no treatment, placebo or another intervention as the comparator were eligible for inclusion. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trials for inclusion, risk of bias and extracted the data. Data were checked for accuracy. MAIN RESULTS: We included four randomised controlled trials (all conducted in Italy) reporting on 567 women who were less than 11 weeks' to 24 weeks' pregnant at the start of the trials. The trials had small sample sizes and one trial only reported an interim analysis. Two trials were open-label. The overall risk of bias was unclear.For the mother, supplementation with myo-inositol was associated with a reduction in the incidence of gestational diabetes compared with control (risk ratio (RR) 0.43, 95% confidence interval (CI) 0.29 to 0.64; three trials; n = 502 women). Using GRADE methods this evidence was assessed as low with downgrading due to unclear risk of bias for allocation concealment in two of the included trials and lack of generalisability of findings. For women who received myo-inositol supplementation, the incidence of GDM ranged from 8% to 18%; for women in the control group, the incidence of GDM was 28%, using International Association of Diabetes and Pregnancy Study Groups Consensus Panel 2010 criteria to diagnose GDM.Two trials reported on hypertensive disorders of pregnancy, a primary maternal outcome of this review. There was no clear difference in risk of hypertensive disorders of pregnancy between the myo-inositol and control groups (average RR 0.43, 95% CI 0.02 to 8.41; two trials; n = 398 women; Tau(2) = 3.23; I(2) = 69%). Using GRADE methods, this evidence was assessed as very low, with downgrading due to wide confidence intervals with very low event rates, a small sample size, and lack of blinding and unclear allocation concealment methods, and a lack of generalisability. For women who received myo-inositol the risk of hypertensive disorders of pregnancy ranged from 0% to 33%; for women in the control group the risk was 4%.For the infant, none of the included trials reported on the primary neonatal outcomes of this systematic review (large-for-gestational age, perinatal mortality, mortality or morbidity composite).In terms of this review's secondary outcomes, there was no clear difference in the risk of caesarean section between the myo-inositol and control groups (RR 0.95, 95% CI 0.76 to 1.19; two trials; n = 398 women). Using GRADE methods, this evidence was assessed as low, with downgrading due to unclear risk of bias in one trial and lack of generalisability. For women who received myo-inositol supplementation, the risk of having a caesarean section ranged from 34% to 54%; for women in the control group the was 45%. There were no maternal adverse effects of therapy in the two trials that reported on this outcome (the other two trials did not report this outcome).Two trials found no clear difference in the risk of macrosomia between infants whose mothers received myo-inositol supplementation compared with controls (average RR 0.35, 95% CI 0.02 to 6.37; two trials; n = 398 infants;Tau(2) = 3.33; I(2) = 73%). Similarly, there was no clear difference between groups in terms of neonatal hypoglycaemia (RR 0.36, 95% CI 0.01 to 8.66) or shoulder dystocia (average RR 2.33, 95% CI 0.12 to 44.30, Tau(2) = 3.24; I(2) = 72%).There was a lack of data available for a large number of m

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd011507.pub2

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 27

  1. D'Anna, 2013, Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study, Diabetes Care, 36, 854, 10.2337/dc12-1371 · DOI · Paper page
  2. D'Anna, 2015, Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial, Obstetrics & Gynecology, 126, 310, 10.1097/AOG.0000000000000958 · DOI · Paper page
  3. D'Anna, 2015, Myo-inositol in the prevention of gestational diabetes and its complications, Pregnancy Hypertension, 5, 6, 10.1016/j.preghy.2014.10.015 · DOI
  4. Facchinetti, 2013, Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial, American Journal of Obstetrics and Gynecology, 208, S36, 10.1016/j.ajog.2012.10.234 · DOI
  5. Malvasi, 2014, Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation, European Review for Medical and Pharmacological Sciences, 18, 270
  6. Corrado, 2011, The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes, Diabetic Medicine, 28, 972, 10.1111/j.1464-5491.2011.03284.x · DOI · Paper page
  7. Alberti, 1998, Definition, diagnosis and classification of diabetes mellitus. Part 1: Diagnosis and classification of diabetes mellitus: World Health Organization Report, Diabetic Medicine, 15, 539, 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
  8. Ali, 2011, Diabetes in pregnancy: health risks and management, Postgraduate Medical Journal, 87, 417, 10.1136/pgmj.2010.109157 · DOI · Paper page
  9. Carlomagno, 2011, Myo-inositol in the treatment of premenstrual dysphoric disorder, Human Psychopharmacology: Clinical and Experimental, 26, 526, 10.1002/hup.1241 · DOI
  10. Croze, 2013, Potential role and therapeutic interests of myo-inositol in metabolic diseases, Biochimie, 95, 1811, 10.1016/j.biochi.2013.05.011 · DOI · Paper page
  11. D'Anna, 2012, Myo-inositol may prevent gestational diabetes in PCOS women, Gynecological Endocrinology, 28, 440, 10.3109/09513590.2011.633665 · DOI · Paper page
  12. Benedetto, 2013, New evidence on inositol supplementation in gestational diabetes, Giornale Italiano di Diabetologia e Metabolismo, 33, 199
  13. Glueck, 2008, Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovarian syndrome, Fertility and Sterility, 89, 625, 10.1016/j.fertnstert.2007.03.036 · DOI
  14. Kennington, 1990, Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus, New England Journal of Medicine, 323, 373, 10.1056/NEJM199008093230603 · DOI · Paper page
  15. Minozzi, 2008, Treatment of hirsutism with myo-inositol: a prospective clinical study, Reproductive Biomedicine Online, 17, 579, 10.1016/S1472-6483(10)60248-9 · DOI
  16. MInistry of Health, 2014, Screening, diagnosis and management of gestational diabetes in New Zealand: a clinical practice guideline
  17. Nankervis, 2013, Gestational diabetes mellitus-negotiating the confusion, Australian Family Physician, 42, 528
  18. National Institute for Health and Clinical Excellence, 2015, Diabetes in Pregnancy: Management of Diabetes and its Complications from Pre-conception to the Postnatal Period. NICE guidelines [NG3]
  19. Nordio, 2013, Combined treatment with Myo-inositol and selenium ensures euthyroidism in subclinical hypothyroidism patients with autoimmune thyroiditis, Journal of Thyroid Research, 2013, 424163, 10.1155/2013/424163 · DOI
  20. Papaleo, 2007, Myoinositol in patients with polycystic ovarian syndrome: a novel method for ovulation induction, Gynecological Endocrinology, 23, 700, 10.1080/09513590701672405 · DOI · Paper page
  21. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014
  22. Rogozinska, 2015, Nutritional manipulation for the primary prevention of gestational diabetes mellitus: a meta-analysis of randomised studies, PLoS One, 10, e0115526, 10.1371/journal.pone.0115526 · DOI · Paper page
  23. Silverman, 1998, Long-term effects of the intrauterine environment: The Northwestern University Diabetes in Pregnancy Center, Diabetes Care, 21 (Suppl. 2), B142
  24. Suzuki, 1994, Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type 2 diabetes, Diabetes Care, 17, 1465, 10.2337/diacare.17.12.1465 · DOI · Paper page
  25. Tieu, 2008, Dietary advice in pregnancy for preventing gestational diabetes mellitus, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006674.pub2 · DOI · Paper page
  26. Unfer, 2011, Effect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort study, Gynecological Endocrinology, 27, 857, 10.3109/09513590.2011.564687 · DOI · Paper page
  27. Brown, 2015, Myo-inositol for preventing gestational diabetes, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD011507 · DOI

Cited by

See all 96

Metadata

Authors
Crawford, T. J., Crowther, C. A., Alsweiler, J., & Brown, J.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2015-12-17
Volume
2015
Issue
12
Pages
CD011507-CD011507
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2227264641
Cited by
96
References
12
FWCI
8.75
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.